000513:SZSELivzon Pharmaceutical Group Inc. Analysis

Livzon Pharmaceutical (000513.SZ) is trading at CNY 30.73, which sits below its 20‑day SMA of 31.78 and well under the 50‑day and 200‑day SMAs, signaling a bearish price trend. The RSI at 28.5 points to an oversold condition, while the MACD histogram remains negative, confirming bearish momentum. Price is hovering just above the identified support level of 30.54, but volume has been decreasing, suggesting limited buying pressure. Despite the technical weakness, the DCF‑derived fair value of roughly CNY 36 implies a potential upside of around 27% from current levels. The stock’s PE ratio of 13.9 is far below the industry average of 27.6, indicating a valuation discount. Additionally, a dividend yield of 3.58% with a payout ratio near 50% and a low beta (~0.06) provide defensive attributes.
From a fundamentals perspective, the company maintains strong profitability margins (gross 66%, operating 29%) and a solid cash position exceeding CNY 9.9 bn against modest debt, resulting in a healthy debt‑to‑equity of ~19%. However, revenue has contracted by roughly 9.7% YoY, which tempers growth expectations. The combination of attractive valuation, sustainable dividend, and low volatility (15% 30‑day) supports a value‑oriented investment case, while the technical setup suggests caution in the near term. Overall, the stock appears undervalued with decent upside potential, but investors should monitor price action around support and volume trends.